Alzheimer's disease
NICE Still Not Recommending Leqembi, Kisunla for Alzheimer's in Updated Draft Guidance
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
Rush U. Gets $10M Philanthropic Gift for Precision Alzheimer's Disease Research
Researchers will use the funds to identify molecular signatures linked to different disease subtypes and test drugs on brain organoids.
EC Resumes Review of Eisai, Biogen's Leqembi Application After CHMP Reaffirms Positive Opinion
The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.
At Some Hospitals, Expert Panels Help Guide Anti-Amyloid Drug Decisions for Alzheimer's Patients
Premium
These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such programs are necessary.
Eisai, Biogen's Leqembi Receives FDA Approval for Chronic Alzheimer's Maintenance Treatment
With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.
Jan 15, 2025
Oct 28, 2024
AbbVie to Buy Aliada Therapeutics for $1.4B in Cash
Oct 16, 2024
Sunbird Bio Nabs $14M in Financing
Oct 9, 2024